Search
Edesa Biotech Inc
EDSAAdd to Watchlist
3.970USD
-0.100-2.46%
Close 09-23 16:00（ET）
38.23MMarket Cap
LossP/E TTM
About Edesa Biotech Inc Company
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Edesa Biotech Inc Profile
Ticker SymbolEDSA
Company nameEdesa Biotech Inc
IPO dateAug 25, 2008
CEONijhawan (Pardeep)
Number of employees16
Security typeOrdinary Share
Fiscal year-endAug 25
Address100 Spy Crt
CityMARKHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeL3R 5H6
Phone19054751234
Websitehttps://www.edesabiotech.com/
Ticker SymbolEDSA
IPO dateAug 25, 2008
CEONijhawan (Pardeep)
Company Executives of Edesa Biotech Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Pardeep (Par) Nijhawan, M.D.
Dr. Pardeep (Par) Nijhawan, M.D.
Chief Executive Officer, Corporate Secretary, Director
Chief Executive Officer, Corporate Secretary, Director
844.81K
+0.68%
Dr. Pardeep (Par) Nijhawan, M.D.
Dr. Pardeep (Par) Nijhawan, M.D.
Chief Executive Officer, Corporate Secretary, Director
Chief Executive Officer, Corporate Secretary, Director
844.81K
+0.68%
Dr. Pardeep (Par) Nijhawan, M.D.
Dr. Pardeep (Par) Nijhawan, M.D.
Chief Executive Officer, Corporate Secretary, Director
Chief Executive Officer, Corporate Secretary, Director
844.81K
+0.68%
Mr. Patrick Marshall
Mr. Patrick Marshall
Independent Director
Independent Director
72.13K
+26.34%
Mr. Patrick Marshall
Mr. Patrick Marshall
Independent Director
Independent Director
72.13K
+26.34%
Mr. Patrick Marshall
Mr. Patrick Marshall
Independent Director
Independent Director
72.13K
+26.34%
Mr. Carlo Sistilli, CPA
Mr. Carlo Sistilli, CPA
Independent Chairman of the Board
Independent Chairman of the Board
49.94K
+38.05%
Mr. Carlo Sistilli, CPA
Mr. Carlo Sistilli, CPA
Independent Chairman of the Board
Independent Chairman of the Board
49.94K
+38.05%
Mr. Carlo Sistilli, CPA
Mr. Carlo Sistilli, CPA
Independent Chairman of the Board
Independent Chairman of the Board
49.94K
+38.05%
Ms. Joan Chypyha
Ms. Joan Chypyha
Independent Director
Independent Director
30.03K
+63.27%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Pardeep (Par) Nijhawan, M.D.
Dr. Pardeep (Par) Nijhawan, M.D.
Chief Executive Officer, Corporate Secretary, Director
Chief Executive Officer, Corporate Secretary, Director
844.81K
+0.68%
Dr. Pardeep (Par) Nijhawan, M.D.
Dr. Pardeep (Par) Nijhawan, M.D.
Chief Executive Officer, Corporate Secretary, Director
Chief Executive Officer, Corporate Secretary, Director
844.81K
+0.68%
Dr. Pardeep (Par) Nijhawan, M.D.
Dr. Pardeep (Par) Nijhawan, M.D.
Chief Executive Officer, Corporate Secretary, Director
Chief Executive Officer, Corporate Secretary, Director
844.81K
+0.68%
Mr. Patrick Marshall
Mr. Patrick Marshall
Independent Director
Independent Director
72.13K
+26.34%
Mr. Patrick Marshall
Mr. Patrick Marshall
Independent Director
Independent Director
72.13K
+26.34%
Mr. Patrick Marshall
Mr. Patrick Marshall
Independent Director
Independent Director
72.13K
+26.34%
FAQs
Who are the top five shareholders of Edesa Biotech Inc?
The top five shareholders of Edesa Biotech Inc are: Dr. Pardeep (Par) Nijhawan, M.D.
How many institutions hold shares of Edesa Biotech Inc (EDSA)?
As of 2026Q1, 47 institutions hold shares of Edesa Biotech Inc, with a combined market value of approximately 4.36M, accounting for 49.07% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1326453.00.